Clinical characteristics of patients with Parkinson’s disease
Keywords:
tremor, Parkinson's disease, motor symptoms, medical treatmentAbstract
Introduction: Parkinson's disease is one of the most frequent neurodegenerative diseases of the motor system that affects the quality of life of the patient.
Methods: A descriptive study was carried out, which included patients with diagnosis of Parkinson's disease, treated in the Movement Disorders Clinic of the International Center for Neurological Restoration (CIREN) from October 2018 to October 2019, sample consisted of 100 patients with Parkinson's disease.
Results: The average age was 60.21% years; the most affected group was that of 60 to 69 years old, the predominant sex was male; 38% were university students; 50% were in stage II of the Hoehn and Yarh scale; 44% were in the group of 1 to 5 years of evolution of the disease, the first symptom that appeared in the disease was tremor in 56%; 58% had sleep disorders and 51% depression; the most percent of the patients had medical treatment levodopa / carbidopa; 55% had a history of previous falls.
Conclusions: Knowing the clinical-epidemiological characteristics and the repercussion that this disease represents for the patient from the psychic, physical and social point of view will make easier its diagnosis and medical treatment.
References
Cacabelos R, Parkinson’sDesease: FromPathogenesistoPharmacogenomics,Int J Mol Sci2017; 18(3): 551.
Castro Toro A, Freddy Buriticá O, Enfermedad de Parkinson: criterios diagnósticos, factores de riesgo y de progresión, y escalas de valoración del estadio clínico, Act Neurol Colomb2014; 30(4):300-6.
Preux PM, Codet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, Couratier P, Boutros-Toni F, Dumas M, Parkinson's disease and environmental factors, Matched casecontrolstudy in the Limousin region, France, Neuroepidemiology 2000; 19(6):333-7.
Rey Pérez A, Enfermedad de Parkinson y otros Parkinsonism’s, Madrid: Médica Panamericana,2009.
Dexter D, Jenner P, Parkinson disease: from pathology to molecular disease mechanisms, Free Radic Biol Med 2013; (62):132-44.
Martínez Jurado E, Cervantes Arriaga A, Rodríguez Violante ,Calidad de vida en pacientes con enfermedad de Parkinson, Rev,MexNeuroci 2010; 11(6):480-86.
Capriotti T, Terzakis K, “Parkinson Disease,” Home Healthcare Now ,2016; 34(6): 300-7.
Fritsch, Thomas, Kathleen A, Smyth, Maggie S, Wallendal, Trevor Hyde, et al, “Parkinson Disease: Research Update and Clinical Management,” Southern Medical Journal2016, 105(12): 650–56.
Jankovic Progression of Parkinson’s disease. Are we making progress in charting the course? Arch Neurol2005; 62:351-52.
Giroud Benítez JL, Collado-Mesa F, Esteban EM, [Prevalence of Parkinson disease in an urban area of the Ciudad de La Habana province, Cuba,Doortodoor population Study Neurología 2000; 15(7):269-73.
Cuba, Ministerio de Salud Pública, Anuario Estadístico de Salud: 2012 [Internet] La Habana: MINSAP, 2013 [citado 7 marzo 2018] Disponible en: http://files.sld.cu/dne/files/2013/04/anuario_2012.pdf
Álvarez Sánchez M, Bases metodológicas, En: Guías de prácticas clínicas basadas en la evidencia Enfermedad de Parkinson, La Habana: Editorial ECIMED 2011:1.
Gallo P, Ewing C, Parkinson's disease: A comprehensive approach to exercise prescription for the health fitness professional, ACSMs Health Fit J 2011; 15(4): 8-17.
Marcos Plasencia LM, Padrón Sánchez A, Protocolo para la alimentación- nutrición en la atención integral al paciente con enfermedad de Parkinson Medisur 2011; 9(3).
Weiner WJ, Early diagnosis of Parkinson's disease and initiation of treatment, Rev Neurol Dis 2008; 5(2):46-53.
Allison W, Willis, Callen Sterling, Brad A, Racette, Conjugal Parkinsonism and Parkinson disease: A case series with environmental risk factor analysis,Parkinsonism’s and RelatadDisorders,2010; 16: 163–6.
Salvador Tranche Iparraguirre, Enfermedad de Parkinson, FMC 2010; 17(8):545-9.
Puy-Núñez A, Cebrián-Pérez EM, Tratamiento inicial de la enfermedad de Parkinson clínicamente establecida, Rev Neurol2012; 54(5): 9-14.
Dhall, Rohit, et al, “Advances in Levodopa Therapy for Parkinson Disease: Review of RYTARY (carbidopa and Levodopa) Clinical Efficacy and Safety,” Neurology 2016; 86 (14).
Kulisevskya J, LuquinMR,Arbeloc JM, Burguerad JA, Carrilloe F, Cast-off A, Chacóng J, et al, Statement Advanced Parkinson’s disease: Clinical characteristics and treatment, Part II,Neurology2013; 28(9):558-83.
Martinez-Fernandez R, Schmitt E, Martinez-Martin P, Krack P, “The Hidden Sister of Motor Fluctuations in Parkinson’s Disease: A Review on No motor Fluctuations,” Movement Disorders: Official Journal of the Movement Disorder Society2016; 31(8).
Gibb WR, Lees AJ, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease, J Neurol Neurosurg Psychiatry 1988; 51:745-52.
Ariza L, Guerrero J, Ortiz P, Moreno C,Caracterización de pacientes con enfermedad de Parkinson en un centro de referencia de la ciudad de Bogotá, Acta Neurol Colomb[Internet] 2016, Sept, [Citado el 25 de enero del 2018]; 32(3) Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482016000300004
Rodríguez M, Villar A, Valencia C, Cervantes A, Características epidemiológicas de pacientes con enfermedad de Parkinson de un hospital de referencia en México,Arch Neurocien (Mex) 2011; 16(2):64-8.
Pedroso Ibáñez I, Álvarez González L, López Flores G, Macías R, Maragoto C, Padrón A, Cirugía lesional como una alternativa de tratamiento quirúrgico en la enfermedad de Parkinson, Revista Mexicana de Neurocirugía2006; 7 (6).
Llumiguano CDTBI, Tratamiento de la enfermedad de Parkinson con palidotomía y palido-talamotomía estereotáctica guiada por microelectrodos 2006:420-32,
Bower JH, Maraganore DM, McDonnell SK, Rocca WA, Incidence and distribution of Parkinsonism in Olmsted County, Minnesota, 1976-1990,Neurology 1999; 52: 1214-20,
Navarro-Peternella FM, Marcon SS, Calidad de vida de las personas con Enfermedad de Parkinson y su relación con la evolución en el tiempo y la gravedad de la enfermedad, Rev Latino-Am Enfermagem. 2012;20(2).
Rodriguez de Paula F, Teixeira-Salmela LF, Faria, Brito PR, Cardoso F, Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson´s disease, Mov Disord 2006; 21(8):1073-7.
Li H, Zhang M, Chen L, Zhang J, Zhong P, Hu A et al, Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson´s disease, Mov Disord 2010; 25(16):2740-6,
Benavides O, Alburquerque D, Chaná P,Evaluación de la sobrecarga en los cuidadores de los pacientes con enfermedad de Parkinson ambulatorios y sus factores de riesgo Rev, MedChile Sant 2013;141 (3).
Llumiguano CDTBI, Tratamiento de la enfermedad de Parkinson con palidotomía y palido-talamotomía estereotáctica guiada por microelectrodos. 2006:420-32.
Torres L, Villa fuerte M, Cosentino C, Flores M, Vélez M, Suárez R, Núñez C, Característicasclínicas de la enfermedad de Parkinson en una cohorte de pacientes peruanos,Rev Per Neurol2012; 13 (1),
Wooten GF, Currie LJ, Bovbjerg VE, Lee JK PJ. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 2004; 75:637-39,
Taylor KS, Cook JA CC, Heterogeneity in male to female risk for Parkinson’s disease, J Neurol Neurosurg Psychiatry2007; 78:905 -6,
Giroud Benítez JL, Collado-Mesa F, Esteban EM, [Prevalence of Parkinson disease in an urban area of the Ciudad de La Habana province, Cuba, Door-todoor population Study], Neurología 2000;15(7):269-73.
Giroud JL, Collado-Mesa F, Orta A, Paz L. Factores de riesgo de la enfermedad de Parkinson idiopática, Estudio de casos y controles en un área urbana de Ciudad Habana, Cuba. Rev Mex Neurocien 2001;2(5): 293-7
Souza RG, Borges V, Silva SMCA, Ferraz HB, Quality of life scale in Parkinson´s disease: PDQ-39 (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation. Arq Neuro psiquiatr. 2007; 65(3-B):787-91.
Berganzo K, Tijero B, Gonzales Eizaguirre A, Somme J, Lezcano E, et al. Síntomas no motores y motores en la enfermedad de Parkinson y su relación con la calidad de visa y los distintos subgrupos clínicos, Neurología 2016; 31(9):585-91.
Downloads
Published
How to Cite
Issue
Section
License
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
